A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia

Phase 2

• Conditions: Hyperlipidemia
• Interventions: Drug: Atorvastatin; Drug: Rosuvastatin

• Registration Number: NCT02979704
• Lead Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Brief Summary

This study will be conducted to assess the status of oxidative stress inflammation and thrombogenesis in patients with hyperlipidemia and to compare the antioxidative, anti-inflammatory and antithrombogenic effects of rosuvastatin and atorvastatin.

Detailed Description

Hyperlipidemia is the major risk factor for development of atherosclerosis which ultimately leads to cardiovascular disease (CVD), an important cause of mortality and morbidity worldwide. Atherosclerosis was previously considered as a lipid storage disease but now growing evidence indicates that increased oxidative stress, vascular inflammation and platelet activation play an important role in the initiation and progression of atherosclerosis. Among the hypolipidemic drugs, statins, 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, have proved to be very much effective. Therefore, statins are the most widely used hypolipidemic agents. Evidence shows that besides hypolipidemic action statins possess antioxidative, anti-inflammatory and antithrombogenic effects known as pleiotropic action which might play an important role in attenuating the atherosclerotic process. However, pleiotropic effect varies with different members of statins.

The present prospective interventional study would be conducted in the Department of Pharmacology, Department of Cardiology and Internal Medicine, BSMMU from March 2016 to August 2017. Total 90 cases will be selected according to inclusion and exclusion criteria. The cases will be subdivided into 2 groups: group A and B. Group A consisting of 45 patients who will receive rosuvastatin (5-10) mg orally once daily and Group B consisting of 45 patients who will receive atorvastatin (10-20) mg orally once daily for 08 weeks. Patient's blood sample will be collected to measure baseline lipid profile, malondialdehyde (MDA), erythrocytic glutathione (GSH), high sensitive C-reactive protein (hs-CRP), prothrombin time (PT), platelet count. After obtaining baseline data patients will be assigned to the respective group. Parameters of baseline will again be evaluated after 08 weeks of therapeutic intervention. Regularity of drug intake will be ensured over telephone, pill count, and from the patient's compliance sheet. Patient's data will be recorded in a predetermined data sheet. Patients will be informed about study, its merits and demerits in easy language and then informed consent will be taken.Therefore, the present study has been designed to compare the antioxidative, anti-inflammatory and antithrombogenic effects of rosuvastatin and atorvastatin in hyperlipidemic patients to establish the superiority of a particular statin, so that it will provide a better therapeutic option in order to prevent CVD related mortality and morbidity.

Study Timeline

• Status Verified: 2016-08
• Study First Submitted: 2016-08-31
• Study Start: 2016-09
• Study First Submitted QC: 2016-12-01
• Last Update Submitted: 2016-12-01
• Study First Posted: 2016-12-02
• Last Update Posted: 2016-12-02
• Primary Completion: 2017-06
• Study Completion: 2017-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Atorvastatin	Atorvastatin	Intervention: Tablet Atorvastatin (10-20) mg orally once daily dose for 08 weeks
Rosuvastatin	Rosuvastatin	Intervention: Tablet Rosuvastatin (5-10) mg orally once daily dose for 08 weeks.

Primary Outcome Measures

Name	Time	Method
Establishment of superiority between rosuvastatin and atorvastatin on reduction of MDA in patients with hyperlipidemia	[0 weeks (baseline), 8 weeks (end)] [safety Issue: No]	Reduction of oxidative stress will be measured by changes in level of MDA in µmol/L
Establishment of superiority between rosuvastatin and atorvastatin on reduction of inflammation in patients with hyperlipidemia	[0 weeks (baseline), 8 weeks (end)] [safety Issue: No]	Reduction of inflammation will be measured by change in level of hs-CRP in mg/L
Establishment of superiority between rosuvastatin and atorvastatin on reduction platelet count in patients with hyperlipidemia	[0 weeks (baseline), 8 weeks (end)] [safety Issue: No]	Reduction of thrombogenesis will be measured by changes in level of platelet count in per L of blood
Establishment of superiority between rosuvastatin and atorvastatin on increase prothrombin time in patients with hyperlipidemia	[0 weeks (baseline), 8 weeks (end)] [safety Issue: No]	Reduction of thrombogenesis will be measured by changes in level of prothrombin time in per sec
Establishment of superiority between rosuvastatin and atorvastatin on increase level of erythrocytic GSH in patients with hyperlipidemia	[0 weeks (baseline), 8 weeks (end)] [safety Issue: No]	Reduction of oxidative stress will be measured by changes in level of erythrocytic GSH in mg/gm of Hb

Trial Locations

Locations (1)

BSMMU; 🇧🇩 Dhaka, Bangladesh